Sri Trang Gloves (Thailand) Public Company Limited

SET:STGT Stock Report

Market Cap: ฿32.1b

Sri Trang Gloves (Thailand) Valuation

Is STGT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of STGT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: STGT (THB11.2) is trading above our estimate of fair value (THB3.55)

Significantly Below Fair Value: STGT is trading above our estimate of fair value.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for STGT?

Other financial metrics that can be useful for relative valuation.

STGT key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.5x
Enterprise Value/EBITDA15.6x
PEG Ratio1.7x

Price to Earnings Ratio vs Peers

How does STGT's PE Ratio compare to its peers?

The above table shows the PE ratio for STGT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average23.2x
TOG Thai Optical Group
11.3xn/a฿4.8b
CHG Chularat Hospital
30x12.3%฿31.7b
BCH Bangkok Chain Hospital
31.8x12.1%฿46.6b
RAM Ramkhamhaeng Hospital
19.8x9.9%฿28.3b
STGT Sri Trang Gloves (Thailand)
60.5x35.9%฿32.1b

Price-To-Earnings vs Peers: STGT is expensive based on its Price-To-Earnings Ratio (60.5x) compared to the peer average (23.2x).


Price to Earnings Ratio vs Industry

How does STGT's PE Ratio compare vs other companies in the Asian Medical Equipment Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a21.2%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a21.2%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: STGT is expensive based on its Price-To-Earnings Ratio (60.5x) compared to the Asian Medical Equipment industry average (24.9x).


Price to Earnings Ratio vs Fair Ratio

What is STGT's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

STGT PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio60.5x
Fair PE Ratio48.5x

Price-To-Earnings vs Fair Ratio: STGT is expensive based on its Price-To-Earnings Ratio (60.5x) compared to the estimated Fair Price-To-Earnings Ratio (48.5x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst STGT forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current฿11.20
฿13.87
+23.8%
3.0%฿14.28฿13.45n/a2
Oct ’25฿12.60
฿13.87
+10.0%
3.0%฿14.28฿13.45n/a2
Sep ’25฿10.60
฿13.87
+30.8%
3.0%฿14.28฿13.45n/a2
Sep ’24฿7.35
฿10.10
+37.4%
1.0%฿10.20฿10.00฿10.602
Aug ’24฿7.20
฿10.10
+40.3%
1.0%฿10.20฿10.00฿9.102
Jul ’24฿7.45
฿8.83
+18.6%
20.3%฿10.20฿6.30฿10.003
Jun ’24฿9.20
฿8.83
-4.0%
20.3%฿10.20฿6.30฿11.203
May ’24฿9.10
฿8.83
-2.9%
20.3%฿10.20฿6.30฿9.253
Apr ’24฿10.20
฿8.83
-13.4%
20.3%฿10.20฿6.30฿8.853
Mar ’24฿11.10
฿11.46
+3.2%
30.6%฿15.60฿6.30฿8.455
Feb ’24฿10.50
฿11.30
+7.6%
31.7%฿15.60฿6.30฿7.005
Jan ’24฿10.00
฿11.30
+13.0%
31.7%฿15.60฿6.30฿6.705
Dec ’23฿9.90
฿12.75
+28.8%
36.1%฿20.00฿6.30฿6.206
Nov ’23฿11.30
฿14.70
+30.1%
27.3%฿20.00฿6.30฿5.807
Oct ’23฿11.40
฿14.70
+28.9%
27.3%฿20.00฿6.30฿6.657

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.


Discover undervalued companies